ERS Genomics licenses CRISPR tech to Aelian

By The Science Advisory Board staff writers

February 11, 2020 -- ERS Genomics announced on February 11 that it has entered an agreement to license its portfolio of CRISPR technology to Aelian Biotechnology.

The announcement comes immediately following the European Patent Office's February 10 rejection of opposition to claims on foundational CRISPR technology in Europe, a ruling that reaffirmed ERS Genomics' position in the field, according to the company.

Per the agreement, ERS Genomics will grant Aelian access to its CRISPR/Cas9 patent portfolio to support the commercial development of Aelian's functional genomic screening platform.

Aelian plans to combine CRISPR screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action. Its platform will function across various cell types to explore broader phenotypes. Under the agreement, Aelian will offer its technology worldwide to pharmaceutical and biotech companies seeking more effective therapies.

Financial details of the agreement were not disclosed.

Opposition fails for key CRISPR patent in Europe
ERS Genomics announced on February 10 that the European Patent Office has upheld an important CRISPR patent, rejecting opposition filed by anonymous parties.
Key CRISPR patent revoked in Europe
An important patent on CRISPR technology held by the Broad Institute has been revoked by the European Patent Office.
MilliporeSigma licenses CRISPR tech to Promega
MilliporeSigma announced on December 19 that it has signed a license agreement providing Promega Corp., access to MilliporeSigma's foundational CRISPR...

Copyright © 2020

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter